{
    "organizations": [],
    "uuid": "c874187b0923a281d26b411affebfcb6d10ab4f2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novartis-says-health-canada-approv/brief-novartis-says-health-canada-approved-kisqali-as-initial-therapy-for-certain-breast-cancer-patients-idUSFWN1S90M2",
    "ord_in_thread": 0,
    "title": "BRIEF-Novartis Says Health Canada Approved Kisqali As Initial Therapy For Certain Breast Cancer Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 2 (Reuters) - Novartis AG:\n* HEALTH CANADA APPROVES KISQALIâ„¢ FOR THE TREATMENT OF HR-POSITIVE AND HER2-NEGATIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN IN COMBINATION WITH LETROZOLE AS AN INITIAL ENDOCRINE-BASED THERAPY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-02T20:25:00.000+03:00",
    "crawled": "2018-05-02T18:24:39.051+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "novartis",
        "ag",
        "health",
        "canada",
        "approves",
        "treatment",
        "metastatic",
        "breast",
        "cancer",
        "postmenopausal",
        "woman",
        "combination",
        "letrozole",
        "initial",
        "therapy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}